Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
Election/Restrictions
Applicant’s election without traverse of Group VIII in the reply filed on August 31, 2026, is acknowledged.
Groups I-VII are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim.
Applicant reserved the right to file a divisional or continuation application to the non-elected subject matter.
An action on the merits on claim 19 (Group I) is contained herein.
Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention.
Claims 79-81 and 83-94 are rejected under 35 U.S.C. 102 as being anticipated by Sabine et al. (US Pub. 2007/0298112).
Applicant claims the following composition:
PNG
media_image1.png
132
820
media_image1.png
Greyscale
PNG
media_image2.png
505
513
media_image2.png
Greyscale
PNG
media_image3.png
520
582
media_image3.png
Greyscale
PNG
media_image4.png
586
632
media_image4.png
Greyscale
This reference discloses Applicant’s pharmaceutical compositions on pages 2 (paragraphs [0028]-[0029]), 5, 6 (paragraphs [0071]-[0073]), 14 (Example 1), 1s 15-16 (Examples 8-11) and figures 18 and 23. (See Abstract Tables, Examples and page 23 and entire document). The pharmaceutical compositions read on the instant claims. Since this reference teaches the exact pharmaceutical compositions, Applicant’s claims are anticipated, and thus, rejected under 35 U.S.C. 102.
Conclusion
Claim 19 is pending in this application. Claim 19 is rejected. No claims are allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to PAUL V WARD whose telephone number is (571)272-2909. The examiner can normally be reached M-F 9am to 5pm.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James Alstrum-Acevedo can be reached at 571-272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/PAUL V WARD/ Primary Examiner, Art Unit 1622